Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply
Lancet Gastroenterol Hepatol
.
2021 Sep;6(9):688.
doi: 10.1016/S2468-1253(21)00253-3.
Authors
Taku Kobayashi
1
;
HABYABUSA Study Group
Affiliation
1
Center for Advanced IBD Research and Treatment, Kitasato University Kitasato Institute Hospital, Tokyo 108-8642, Japan. Electronic address: kobataku@insti.kitasato-u.ac.jp.
PMID:
34391518
DOI:
10.1016/S2468-1253(21)00253-3
No abstract available
Publication types
Letter
Comment
MeSH terms
Biological Products* / adverse effects
Colitis, Ulcerative* / drug therapy
Humans
Mesalamine
Substances
Biological Products
Mesalamine